Nerandomilast: Breakthrough Success in Phase 3
We would like to introduce the data we obtained from a recently conducted bleomycin-induced lung fibrosis study using Nerandomilast.
Nerandomilast is a compound expected to be approved soon as a treatment for IPF, following the previously approved Pirfenidone and Nintedanib.
The mentioned therapeutic study using Nerandomilast in a bleomycin-induced lung fibrosis model that was conducted at SMC Laboratories showed promising results.
The significance of a positive control in a pharmacology study is to demonstrate the efficacy of the test substance to the same degree as a known effective treatment and to demonstrate the efficacy of the treatment by showing the superiority of the treatment in direct comparison with the positive control. In other words, by establishing a positive control, the drug efficacy of the test substance can be evaluated by comparing it to the positive control.
Do you need a drug efficacy evaluation study with Nerandomilast as positive control?
If you have any questions or requests for more information, please feel free to contact us.